A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone

Psychiatry Research

Volumn 198, Issue 2, 2012, Pages 194-201

  Hatta, Kotaro ^a   Otachi, Taro ^b   Sudo, Yasuhiko ^c   Kuga, Hironori ^d   Takebayashi, Hiroshi ^e   Hayashi, Hideaki ^f   Ishii, Ryusuke ^g   Kasuya, Masataka ^h   Hayakawa, Tatsuro ⁱ   Morikawa, Fumiyoshi ^j   Hata, Kazuya ^k   Nakamura, Mitsuru ^l   Usui, Chie ^a   Nakamura, Hiroyuki ^m   Hirata, Toyoaki ⁿ   Sawa, Yutaka ^o  

^a JUNTENDO UNIVERSITY NERIMA HOSPITAL   (Japan)

^b Gunma Psychiatric Medical Center   (Japan)

^c Tosa Hospital   (Japan)

^d National Hospital Organization Hizen Psychiatric Center   (Japan)

^e Saitama Prefectural Psychiatric Hospital   (Japan)

^f Chiba Psychiatric Medical Center   (Japan)

^g Department of Psychiatry   (Japan)

^h Tokyo Musashino Hospital   (Japan)

ⁱ NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^j Department of Psychiatry   (Japan)

^k Hokuto Clinic Hospital   (Japan)

^l Toshima Tokyo Metropolitan Hospital   (Japan)

^m KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

ⁿ Shizuoka Psychiatric Medical Center   (Japan)

^o Sawa Hospital   (Japan)

more..

Author keywords

Add on; Antipsychotic; Clinical trial; Combination; Emergency; Polypharmacy

Indexed keywords

BENZODIAZEPINE DERIVATIVE; FLUNITRAZEPAM; LORAZEPAM; NITRAZEPAM; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA; SINGLE-BLIND METHOD;

EID: 84868150306     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2012.01.006     Document Type: Article

References (29)

1. Breier A., Meehan K., Birkett M., David S., Ferchland I., Sutton V., Taylor C.C., Palmer R., Dossenbach M., Kiesler G., Brook S., Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry 2002, 59:441-448.
2. Correll C.U. Antipsychotic polypharmacy, Part 2: why use 2 antipsychotics when 1 is not good enough?. The Journal of Clinical Psychiatry 2008, 69:860-861.
3. Correll C.U., Rummel-Kluge C., Corves C., Kane J.M., Leucht S. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophrenia Bulletin 2009, 35:443-457.
4. Edlinger M., Hausmann A., Kemmler G., Kurz M., Kurzthaler I., Walch T., Walpoth M., Fleischhacker W.W. Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period. Schizophrenia Research 2005, 77:25-34.
5. Emsley R.A. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophrenia Bulletin 1999, 25:721-729.
6. Emsley R., Rabinowitz J., Medori R. Time course for antipsychotic treatment response in first-episode schizophrenia. The American Journal of Psychiatry 2006, 163:743-745.
7. Essock A.J.P., Schooler N.R., Stroup T.S., McEvoy J.P., Rojas I., Jackson C., Covell N.H., the Schizophrenia Trials Network Effectiveness of switching from antipsychotic polypharmacy to monotherapy. The American Journal of Psychiatry 2011, 168:702-708.
8. Guy W. ECDEU Assessment Manual for Psychopharmacology 1976, US Dept of Health, Education, and Welfare, Bethesda.
9. Hatta K., Takahashi T., Nakamura H., Yamashiro H., Endo H., Fujii S., Fukami G., Masui K., Asukai N., Yonezawa Y. Abnormal physiological conditions in acute schizophrenic patients on emergency admission: dehydration, hypokalemia, leukocytosis and elevated serum muscle enzymes. European Archives of Psychiatry and Clinical Neuroscience 1998, 248:180-188.
10. Hatta K., Kawabata T., Yoshida K., Hamakawa H., Wakejima T., Furuta K., Nakamura M., Hirata T., Usui C., Nakamura H., Sawa Y. Olanzapine orally disintegrating tablet versus risperidone oral solution in the treatment of acutely agitated psychotic patients. General Hospital Psychiatry 2008, 30:367-371.
11. Hatta K., Sato K., Hamakawa H., Takebayashi H., Kimura N., Ochi S., Sudo Y., Asukai N., Nakamura H., Usui C., Kawabata T., Hirata T., Sawa Y. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia. Schizophrenia Research 2009, 113:49-55.
12. Hatta K., Otachi T., Sudo Y., Hayakawa T., Ashizawa Y., Takebayashi H., Hayashi N., Hamakawa H., Ito S., Nakase R., Usui C., Nakamura H., Hirata T., Sawa Y. Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia. Schizophrenia Research 2011, 128:127-135. for the JAST study group.
13. Inada T. Evaluation and Diagnosis of Drug-induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage 1996, Seiwa Shoten Publishers, Tokyo.
14. Jones S.H., Thornicroft G., Coffey M., Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). The British Journal of Psychiatry 1995, 166:654-659.
15. Kane J.M., Leucht S. Unanswered questions in schizophrenia clinical trials. Schizophrenia Bulletin 2008, 34:302-309.
16. Kane J.M., Leucht S., Carpenter D., Docherty J.P. Optimizing pharmacologic treatment of psychotic disorders. The Journal of Clinical Psychiatry 2003, 64(suppl 12):1-100.
17. Kane J.M., Correll C.U., Goff D.C., Kirkpatrick B., Marder S.R., Vester-Blokland E., Sun W., Carson W.H., Pikalov A., Assunção-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. The Journal of Clinical Psychiatry 2009, 70:1348-1357.
18. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Rating Manual 1991, Multi-Health System Inc, Toronto.
19. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Sniadecki J.L., Kane J.M. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophrenia Research 2008, 102:230-240.
20. Kinon B.J., Chen L., Ascher-Svanum H., Stauffer V.L., Kollack-Walker S., Zhou W., Kapur S., Kane J.M. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 2010, 35:581-590.
21. Kopala L.C., Good K.P., Honer W.G. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. Journal of Clinical Psychopharmacology 1997, 17:308-313.
22. Kotler M., Strous R.D., Reznik I., Shwartz S., Weizman A., Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology. International Clinical Psychopharmacology 2004, 19:23-26.
23. Lane H.Y., Chiu W.C., Chou J.C., Wu S.T., Su M.H., Chang W.H. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. The Journal of Clinical Psychiatry 2000, 61:209-214.
24. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., Engel R.R. What does the PANSS mean?. Schizophrenia Research 2005, 79:231-238.
25. Leucht S., Davis J.M., Engel R.R., Kissling W., Kane J.M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatrica Scandinavica 2009, 119(Suppl 438):7-14.
26. Love R.C., Conley R.R., Kelly D.L., Bartko J.J. A dose-outcome analysis of risperidone. Journal of Clinical Psychiatry 1999, 60:771-775.
27. Stauffer V.L., Case M., Kinon B.J., Conley R., Ascher-Svanum H., Kollack-Walker S., Kane J., McEvoy J., Lieberman J. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. Psychiatry Research 2011, 187:42-48.
28. Suzuki T., Uchida H., Watanabe K., Nakajima S., Nomura K., Takeuchi H., Tanabe A., Yagi G., Kashima H. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Human Psychopharmacology 2008, 23:455-463.
29. Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. The American Journal of Psychiatry 2002, 159:255-262.